ZAI LAB (09688): Latest Update on Amgen's Bemarituzumab FORTITUDE-101 Phase III Clinical Trial

Stock News

Sep 03

ZAI LAB (09688) announced that according to Amgen, the company's partner and sponsor of the study, the FORTITUDE-101 Phase III clinical trial evaluating bemarituzumab in combination with chemotherapy (mFOLFOX6) for first-line gastric cancer treatment has completed its final analysis. During the study's pre-specified interim analysis (the primary analysis), the bemarituzumab plus chemotherapy regimen demonstrated statistically significant and clinically meaningful improvement in overall survival compared to chemotherapy alone. However, in the final analysis, the previously observed survival benefit magnitude was diminished. Amgen stated that results from both the interim and final analyses will be presented at upcoming major medical conferences. Based on the updated results from the FORTITUDE-101 study, the company plans to await results from the FORTITUDE-102 study (which aims to evaluate bemarituzumab in combination with nivolumab plus chemotherapy in the same patient population) before submitting registration applications. Data from the FORTITUDE-102 study is expected to be released in late 2025 or the first half of 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1130124562"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1130124562\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1130124562?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-03 22:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1130124562","market":"sg","top_or_hot":-1,"title":"ZAI LAB (09688): Latest Update on Amgen's Bemarituzumab FORTITUDE-101 Phase III Clinical Trial","media":"Stock News","content":"<p>ZAI LAB (09688) announced that according to Amgen, the company's partner and sponsor of the study, the FORTITUDE-101 Phase III clinical trial evaluating bemarituzumab in combination with chemotherapy (mFOLFOX6) for first-line gastric cancer treatment has completed its final analysis. During the study's pre-specified interim analysis (the primary analysis), the bemarituzumab plus chemotherapy regimen demonstrated statistically significant and clinically meaningful improvement in overall survival compared to chemotherapy alone. However, in the final analysis, the previously observed survival benefit magnitude was diminished. Amgen stated that results from both the interim and final analyses will be presented at upcoming major medical conferences. Based on the updated results from the FORTITUDE-101 study, the company plans to await results from the FORTITUDE-102 study (which aims to evaluate bemarituzumab in combination with nivolumab plus chemotherapy in the same patient population) before submitting registration applications. Data from the FORTITUDE-102 study is expected to be released in late 2025 or the first half of 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ZAI LAB (09688): Latest Update on Amgen's Bemarituzumab FORTITUDE-101 Phase III Clinical Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZAI LAB (09688): Latest Update on Amgen's Bemarituzumab FORTITUDE-101 Phase III Clinical Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-09-03 22:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ZAI LAB (09688) announced that according to Amgen, the company's partner and sponsor of the study, the FORTITUDE-101 Phase III clinical trial evaluating bemarituzumab in combination with chemotherapy (mFOLFOX6) for first-line gastric cancer treatment has completed its final analysis. During the study's pre-specified interim analysis (the primary analysis), the bemarituzumab plus chemotherapy regimen demonstrated statistically significant and clinically meaningful improvement in overall survival compared to chemotherapy alone. However, in the final analysis, the previously observed survival benefit magnitude was diminished. Amgen stated that results from both the interim and final analyses will be presented at upcoming major medical conferences. Based on the updated results from the FORTITUDE-101 study, the company plans to await results from the FORTITUDE-102 study (which aims to evaluate bemarituzumab in combination with nivolumab plus chemotherapy in the same patient population) before submitting registration applications. Data from the FORTITUDE-102 study is expected to be released in late 2025 or the first half of 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE0009355771.USD","symbol_name":"骏利亨德森环球生命科技A Acc","start_time":0,"source_url":"","article_id":"1130124562","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1130124562","pubTimestamp":1756910423,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"ZAI LAB (09688) announced that according to Amgen, the company's partner and sponsor of the study, the FORTITUDE-101 Phase III clinical trial evaluating bemarituzumab in combination with chemotherapy...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BK4588":"碎股","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","BK4548":"巴美列捷福持仓","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","BK4134":"信息科技咨询与其它服务","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK1588":"回港中概股","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","BK1161":"生物科技","BK4581":"高盛持仓","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","BK4599":"减肥药","BK4531":"中概回港概念","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","BK4526":"热门中概股","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","BK1574":"生物医药B类股","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","AMGN":"安进","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BK4566":"资本集团","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0122379950.USD":"贝莱德世界健康科学A2","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","ZLAB":"再鼎医药","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","III":"信息服务","09688":"再鼎医药","LU0058720904.USD":"联博国际健康护理基金A","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD"},"translate_title":"再鼎医药(09688)：安进bemarituzumab FORTITUDE-101 III期临床试验最新进展","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09688":1,"AMGN":1,"III":1,"ZLAB":1},"content_text":"ZAI LAB (09688) announced that according to Amgen, the company's partner and sponsor of the study, the FORTITUDE-101 Phase III clinical trial evaluating bemarituzumab in combination with chemotherapy (mFOLFOX6) for first-line gastric cancer treatment has completed its final analysis. During the study's pre-specified interim analysis (the primary analysis), the bemarituzumab plus chemotherapy regimen demonstrated statistically significant and clinically meaningful improvement in overall survival compared to chemotherapy alone. However, in the final analysis, the previously observed survival benefit magnitude was diminished. Amgen stated that results from both the interim and final analyses will be presented at upcoming major medical conferences. Based on the updated results from the FORTITUDE-101 study, the company plans to await results from the FORTITUDE-102 study (which aims to evaluate bemarituzumab in combination with nivolumab plus chemotherapy in the same patient population) before submitting registration applications. Data from the FORTITUDE-102 study is expected to be released in late 2025 or the first half of 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}